
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is a promising clinical-stage biotechnology company with a strong proprietary Native Complex Platform that has the potential to unlock the full potential of GPCR therapies. The company has a diversified pipeline of product candidates targeting various therapeutic areas, which could lead to significant revenue potential in the future. With positive data from the Phase 1 clinical trial of its lead candidate SEP-479 and potential lead candidate selection from its TSHR NAM program by the end of this year, Septerna is poised for growth and success in the coming years.
Bears say
Septerna is currently facing significant valuation and risk concerns as evidenced by an 11% discount rate, conservative market assumptions, and a 30% probability of approval for their lead candidate, SEP-479. Additionally, risks to price target achievement include delays in advancing other candidates, setbacks in clinical trials, and possible partnership risks. Though the company has a strong cash position, with enough funds to last until 2029, it remains to be seen if their lead candidate, SEP-631, will meet expectations in mast cell-driven diseases such as chronic inducible urticaria and other inflammatory indications. Overall, given recent competitor data and a reduced 25% probability of success for SEP-631 in CSU, the company's valuation and market share estimates have been adjusted accordingly.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares